About EpilepsyGTx
EpilepsyGTx is a company based in Waterbeach (United Kingdom) founded in 2021.. EpilepsyGTx has raised $43 million across 2 funding rounds from investors including UCL Technology Fund and HTH. EpilepsyGTx offers products and services including EPY201. EpilepsyGTx operates in a competitive market with competitors including Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Marinus Pharma, among others.
- Headquarter Waterbeach, United Kingdom
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$43 M (USD)
in 2 rounds
-
Latest Funding Round
$33 M (USD), Series A
Dec 09, 2025
-
Investors
UCL Technology Fund
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EpilepsyGTx
EpilepsyGTx offers a comprehensive portfolio of products and services, including EPY201. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets seizure focus in focal refractory epilepsy for potential treatment.
Funding Insights of EpilepsyGTx
EpilepsyGTx has successfully raised a total of $43M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $33 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $33.0M
-
First Round
First Round
(24 Jun 2024)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2025 | Amount | Series A - EpilepsyGTx | Valuation |
investors |
|
| Jun, 2024 | Amount | Seed - EpilepsyGTx | Valuation | UCL Technology Fund |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in EpilepsyGTx
EpilepsyGTx has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include UCL Technology Fund and HTH. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on physical and life sciences companies
|
Founded Year | Domain | Location | |
|
HTH is engaged in investing in health technology startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by EpilepsyGTx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - EpilepsyGTx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Epilepsygtx Comparisons
Competitors of EpilepsyGTx
EpilepsyGTx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Marinus Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics to treat seizure disorders
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about EpilepsyGTx
When was EpilepsyGTx founded?
EpilepsyGTx was founded in 2021 and raised its 1st funding round 3 years after it was founded.
Where is EpilepsyGTx located?
EpilepsyGTx is headquartered in Waterbeach, United Kingdom. It is registered at Waterbeach, Cambridgeshire, United Kingdom.
Who is the current CEO of EpilepsyGTx?
Nicolas Koebel is the current CEO of EpilepsyGTx.
Is EpilepsyGTx a funded company?
EpilepsyGTx is a funded company, having raised a total of $43M across 2 funding rounds to date. The company's 1st funding round was a Seed of $10M, raised on Jun 24, 2024.
What does EpilepsyGTx do?
EpilepsyGTx was founded in 2021 in Waterbeach, United Kingdom, as a biotechnology firm focused on gene therapies for focal refractory epilepsy. The companys primary program, EPY201, is based on an AAV9 capsid vector carrying an engineered Kv1.1 potassium channel under a CAMK2A promoter. This therapy is administered directly into the seizure focus via intraparenchymal delivery to target neurological activity. Operations center on advancing clinical-stage interventions in the neurology sector.
Who are the top competitors of EpilepsyGTx?
EpilepsyGTx's top competitors include Vaxcyte, Serum Institute of India and Biological E.
What products or services does EpilepsyGTx offer?
EpilepsyGTx offers EPY201.
Who are EpilepsyGTx's investors?
EpilepsyGTx has 2 investors. Key investors include UCL Technology Fund, and HTH.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.